IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer

ConclusionsIL17RB predicts the prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Source: Pathology Research and Practice - Category: Pathology Source Type: research

Related Links:

Publication date: Available online 10 October 2019Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet, Dominique Béchade, Isabelle Trouilloud, Nelson Lourenco, Vincent Hautefeuille, Christophe Locher, Nicolas Williet, Jérôme Desrame, Pascal Artru, Emilie Soularue, Bertrand Le Roy, Julien TaiebSummaryBackgroundA combination of nab-paclitaxel plus gemcitabine (N + G) has recently become a standard first-line treatment in patients with metastatic pancreatic adenocarcinoma (MPA), but there are currently no publish...
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research
Leone Aglietta Surgical resection remains the only treatment that offers a potential chance of long-term survival. Unfortunately, about 80% of patients treated with curative intent will develop recurrence. Since 2001, adjuvant therapy with gemcitabine or 5-fluorouracyle was recommended. This approach allows a median overall survival (OS) of around 23 months, and 5-year survival of 22%. In recent years, two phase-3 trials investigating new chemotherapy regimens resulted in considerably improved survival times. The doublet gemcitabine–capecitabine has shown improvement in OS from 25.5 to 28 months (p = 0...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
AbstractPurposeDespite advances in various treatment modalities, surgical resection for pancreatic ductal adenocarcinoma (PDA) remains the only curative treatment. Data remains limited regarding survival rates for resectable PDA when managed by a multidisciplinary pancreas conference (MDPC). The aim of this study is to assess survival rates, identify significant predictors of mortality, and assess the benefits of adjuvant chemotherapy for resectable PDA following presentation at a MDPC.MethodsAll patients presented from April 2013 to August 2016 with resectable PDA were discussed at a MDPC at a tertiary care center and wer...
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
Treatment with 9-ING-41 significantly increased pancreatic tumor cell killing when combined with chemotherapy in pre-clinical trials.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Authors: Parker NH, Lee RE, O'Connor DP, Ngo-Huang A, Petzel MQB, Schadler K, Wang X, Xiao L, Fogelman D, Simpson R, Fleming JB, Lee JE, Tzeng CD, Sahai SK, Basen-Engquist K, Katz MHG Abstract BACKGROUND: Physical activity and exercise appear to benefit patients receiving preoperative treatment for cancer. Supports and barriers must be considered to increase compliance with home-based exercise prescriptions in this setting. Such influences have not been previously examined. METHODS: The authors used quantitative and qualitative methods to examine potential physical activity influences among patients who were pr...
Source: Journal of Physical Activity and Health - Category: Sports Medicine Tags: J Phys Act Health Source Type: research
AbstractPurposeThe aim of this study was to assess the validity of surgical resection for patients with pancreatic adenocarcinoma (PDAC) aged ≥80 years stratified by resectability status.MethodsMedical records of 245 with resectable (R) and 169 with borderline resectable/unresectable (BR/UR) PDAC, were reviewed retrospectively. Of the total of 414 patients, 56 (14%) were ≥80 years. The prognostic impact of age ≥80 years was analyzed with stratification by resectability status.ResultsNo significant difference was found in the incidence of major complications between patients aged ≥80 versus
Source: Journal of Hepato-Biliary-Pancreatic Sciences - Category: Gastroenterology Authors: Tags: Original Article Source Type: research
Abstract BACKGROUND: Upper gastrointestinal malignancies have a poor prognosis. There is no consensus on how patients should be followed after surgery. The authors hypothesized that a structured follow-up programme including endoscopic ultrasonography (EUS) and [18 F]fluorodeoxyglucose (FDG) PET/CT would detect cancer recurrences, leading to more patients being eligible for therapy. METHODS: After surgery with curative intent for adenocarcinomas in the gastro-oesophageal junction, stomach or pancreas, patients were randomized 1 : 1 to standard clinical assessment in the outpatient clinic at 3, 6...
Source: The British Journal of Surgery - Category: Surgery Authors: Tags: Br J Surg Source Type: research
MONDAY, Oct. 7, 2019 -- " Jeopardy! " host Alex Trebek hinted in an interview that chemotherapy for stage 4 pancreatic cancer is taking a toll on his ability to host the popular game show. The 79-year-old Trebek resumed chemotherapy last month after...
Source: - Daily MedNews - Category: General Medicine Source Type: news
CONCLUSIONS: PBD is often performed in patients undergoing PD without a formal indication, mainly due to high bilirubin levels. No increased morbidity/mortality was observed but length of hospital stay was prolonged in patients performing PBD. PMID: 31566326 [PubMed - in process]
Source: Acta Gastro-Enterologica Belgica - Category: Gastroenterology Tags: Acta Gastroenterol Belg Source Type: research
Conditions:   Pancreatic Cancer;   Exocrine Pancreatic Insufficiency;   Metastatic Pancreatic Cancer;   Chemotherapy;   Malnutrition;   Locally Advanced Malignant Neoplasm Intervention:   Sponsors:   Moscow Clinical Scientific Center;   University of Santiago de Compostela;   University Clinic Dr Dragisa Misovic-Dedinje;   University of Belgrade;   Hospital General Universitario de Alicante;   Faculty of Medicine, Istanbu...
Source: - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Pancreas | Pancreatic Cancer | Pathology